Zealand Pharma, Roche to advance petrelintide for weight management to Phase 3

Zealand Pharma A/S (ZLDPF) announced formal endorsement to advance petrelintide, an amylin analog for chronic weight management, into Phase 3 trials with its partner Roche (RHHBY). The initiation is planned for the second half of 2026. Adam Steensberg, President and Chief Executive Officer of Zealand Pharma, said, “Advancing petrelintide into Phase 3 marks an important step for the program and our collaboration with Roche. By delivering exceptional tolerability and desired weight loss without disrupting daily life, we aim to redefine the weight management experience for people living with overweight and obesity.” Zealand added: “The Phase 3 program for petrelintide is designed to evaluate the efficacy, safety, and tolerability of petrelintide as a once-weekly subcutaneous treatment in adults living with obesity or overweight with weight-related comorbidities. Petrelintide has the potential to address significant unmet needs in chronic weight management by providing a highly tolerable alternative that promotes long-term adherence, a critical factor for sustained health outcomes.”